Combination treatment before surgery for unresectable esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of treatments given before surgery to shrink tumors in patients with esophageal cancer that is considered too advanced for immediate surgery. The goal is to make surgery possible and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma, confirmed by biopsy.
- Your cancer is in the thoracic (chest) part of the esophagus and has not spread to distant organs.
- You have not had any previous cancer treatment like surgery, radiation, chemotherapy, or immunotherapy.
- Your cancer is considered borderline unresectable (not removable by surgery right now) but might be made removable with treatment.
- You are in good general health with a performance status of 70 or higher on the Karnofsky scale.
- Your blood counts and organ function (kidney, liver) are within normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a single immunotherapy drug (tislelizumab) given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if it can shrink the tumor and improve outcomes.
This trial tests if adding the immunotherapy drug tislelizumab to standard chemotherapy before surgery or radiation can improve outcomes for people with resectable esophageal squamous cell carcinoma. It is designed for patients whose cancer is in the chest and has not spread to distant organs.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy given before and after surgery for esophageal cancer. It aims to see if this approach can improve treatment outcomes for patients with a certain stage of the disease.
This trial tests the safety and effectiveness of combining two immunotherapy drugs (iparomlimab and tuvonralimab) with a chemotherapy drug (nab-paclitaxel) before surgery for people with a certain type of esophageal cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
Hear when a new Esophagus Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.